Table 1.
Baseline demographic and clinical characteristics.
| Characteristics | N(%) |
|---|---|
| Median age (range) - yr | 61.8 (23.5–92.1) |
| <60 yr - no. (%) | 135 (43.5) |
| ≥60 yr - no. (%) | 175 (56.5) |
| Menopausal status - no. (%) | |
| Premenopausal | 57 (18.4) |
| Postmenopausal | 253 (81.6) |
| Initial ECOG performance status - no. (%) | |
| 0 | 160 (59.7) |
| 1 | 86 (32.1) |
| 2 | 22 (8.2) |
| Histologya - no. (%) | |
| Invasive of no special type | 231 (81.0) |
| Invasive lobular | 47 (16.5) |
| Other | 7 (2.5) |
| Estrogen receptora (threshold: 10%) - no. (%) | |
| Positive | 268 (99.3) |
| Negative | 2 (0.7) |
| Progesterone receptora (threshold: 10%) - no. (%) | |
| Positive | 197 (81.4) |
| Negative | 45 (18.6) |
| HER2a - no. (%) | |
| Positive | 0 (0.0) |
| Negative | 239 (100.0) |
| Breast cancer first diagnosis - no. (%) | |
| Early | 227 (73.2) |
| Advanced | 83 (26.8) |
| Stage at diagnosis - no. (%) | |
| Stade I | 44 (14.2) |
| Stade II | 93 (30.0) |
| Stade III | 15 (4.8) |
| NA (localized only) | 75 (24.2) |
| Stade IV | 83 (26.8) |
| Visceral lesion - no. (%) | |
| Yes | 158 (51.0) |
| No | 152 (49.0) |
| Bone-only metastasis - no. (%) | |
| Yes | 100 (32.3%) |
| No | 210 (67.7%) |
| No. of metastatic sites - no. (%) | |
| 1–2 | 223 (71.9) |
| ≥3 | 87 (28.1) |
| Previous systemic treatment - no. (%) | |
| Endocrine therapy | 188 (60.6) |
| Chemotherapy | 157 (49.7) |
| Prior endocrine therapy - no. (%) | |
| Endocrine therapy-naïve | 122 (39.3) |
| Sensibility to endocrine therapy | 96 (31.0) |
| Resistance to endocrine therapy | 92 (29.7) |
| Line - no. (%) | |
| First | 225 (72.6) |
| Second | 85 (27.4) |
| Initiation dose - no. (%) | |
| 125 mg | 295 (95.2) |
| 100 mg | 14 (4.5) |
| 75 mg | 1 (0.3) |
| 3 weeks out of 4 | 310 (100.0) |
| Endocrine therapy - no. (%) | |
| Letrozole | 195 (62.9) |
| Anastrozole | 9 (2.9) |
| Exemestane | 3 (1.0) |
| Fulvestrant | 103 (33.2) |
| LH-RH agonist | 61 (19.7) |
| Denosumab - no. (%) | 170 (74.2) |
| Additional consultation - no. (%) | |
| Clinical nurse | 222 (71.6) |
| Oncogeriatrician | 18 (5.8) |
HER2: Human Epidermal Growth Factor Receptor-2.
LH-RH: luteinizing-hormone-releasing-hormone.
a
In the first histological exam.